See more : BYD Company Limited (002594.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of Clarity Pharmaceuticals Ltd (CU6.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Clarity Pharmaceuticals Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
- Jiang Xi Chenguang New Materials Co.,Ltd. (605399.SS) Income Statement Analysis – Financial Results
- Dhampur Bio Organics Limited (DBOL.NS) Income Statement Analysis – Financial Results
- Lifestyle Global Enterprise Inc. (8066.TWO) Income Statement Analysis – Financial Results
- ValiRx plc (VAL.L) Income Statement Analysis – Financial Results
- Sofcom Systems Limited (SOFCOM.BO) Income Statement Analysis – Financial Results
Clarity Pharmaceuticals Ltd (CU6.AX)
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express gastrin releasing peptide receptor; and SAR-bisPSMA, a theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express prostate specific membrane antigen. The company has collaboration with GU Research Network for an investigator initiated Trial X-Calibur, using 64Cu-SAR-bisPSMA in known or suspected prostate cancer. Clarity Pharmaceuticals Ltd was incorporated in 2010 and is based in Sydney, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|
| Revenue | 11.51M | 9.80M | 6.46M | 3.20M | 2.79M | 2.64M | 2.46M |
| Cost of Revenue | 0.00 | 100.51K | 46.25K | 15.63K | 17.00K | 22.02K | 23.83K |
| Gross Profit | 11.51M | 9.70M | 6.41M | 3.18M | 2.77M | 2.62M | 2.44M |
| Gross Profit Ratio | 100.00% | 98.97% | 99.28% | 99.51% | 99.39% | 99.17% | 99.03% |
| Research & Development | 45.78M | 31.46M | 18.90M | 9.68M | 4.03M | 2.11M | 1.47M |
| General & Administrative | 10.35M | 2.03M | 9.07M | 3.83M | 2.82M | 506.10K | 272.98K |
| Selling & Marketing | 170.84K | 2.58M | 0.00 | -15.67K | 2.98M | 3.77M | 2.44M |
| SG&A | 10.52M | 4.60M | 9.07M | 3.82M | 5.80M | 4.28M | 2.71M |
| Other Expenses | 0.00 | 9.80M | 6.46M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 56.31M | 36.06M | 30.29M | 13.49M | 9.83M | 6.39M | 4.18M |
| Cost & Expenses | 56.31M | 36.16M | 30.29M | 13.51M | 9.85M | 6.41M | 4.20M |
| Interest Income | 2.77M | 1.86M | 95.09K | 41.93K | 59.42K | 81.30K | 19.94K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 153.07K | 100.51K | 46.25K | 15.63K | 17.00K | 22.02K | 23.83K |
| EBITDA | -44.65M | -26.26M | -17.00M | -10.30M | -7.04M | -3.74M | -1.72M |
| EBITDA Ratio | -388.02% | -367.97% | -468.26% | -422.16% | -352.45% | -241.62% | -169.70% |
| Operating Income | -44.80M | -36.16M | -30.29M | -13.51M | -9.85M | -6.41M | -4.20M |
| Operating Income Ratio | -389.35% | -369.00% | -468.98% | -422.65% | -353.06% | -242.45% | -170.67% |
| Total Other Income/Expenses | 2.77M | 11.66M | 5.90M | 116.69K | 405.31K | 1.42M | 991.82K |
| Income Before Tax | -42.03M | -34.30M | -23.74M | -13.39M | -9.44M | -4.99M | -3.21M |
| Income Before Tax Ratio | -365.26% | -349.98% | -367.51% | -418.99% | -338.52% | -188.63% | -130.37% |
| Income Tax Expense | 295.15K | -9.70M | 17.63K | -3.17M | -2.49M | -1.30M | -1.49M |
| Net Income | -42.32M | -24.60M | -23.75M | -10.22M | -6.95M | -3.68M | -1.72M |
| Net Income Ratio | -367.83% | -251.03% | -367.78% | -319.77% | -249.35% | -139.37% | -69.86% |
| EPS | -0.15 | -0.09 | -0.10 | -0.04 | -0.03 | -0.01 | -0.01 |
| EPS Diluted | -0.15 | -0.09 | -0.10 | -0.04 | -0.03 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 273.16M | 260.41M | 248.47M | 256.93M | 256.93M | 256.93M | 256.93M |
| Weighted Avg Shares Out (Dil) | 273.16M | 260.41M | 248.47M | 256.93M | 256.93M | 256.93M | 256.93M |
Source: https://incomestatements.info
Category: Stock Reports